Última actualización :
19/11/2024
fármacos contra el cáncer   Fludarabine phosphate  
Inyectables
Estabilidad en solucion Estabilidad en mezcla Factores que influyen sobre la estabilidad Compatibilidades método de inyección Bibliografía pdf
   Estructura química  

Nombre comercial   Nombre comercial     

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Acetaflur México
Asoleudox México
Beneflur España, México
Fludabin Marruecos
Fludacel India, Marruecos
Fludakebir Marruecos
Fludalym Turquía
Fludara Alemania, Arabia Saudita, Austria, Bélgica, Chile, Colombia, Dinamarca, Egipto, Estados Unidos de América, Finlandia, Francia, Gran Bretaña, Hungría, India, Irán, Irlanda, Italia, Luxemburgo, Malasia, Nueva Zelanda, Países Bajos, Polonia, Portugal, Rumania, Suecia, Suiza, Venezuela
Fludarabin Islandia, Italia, Noruega, Suecia, Suiza
Fludarabina Argentina, Colombia, España, Marruecos, Rumania
Fludarabine Bélgica, Canadá, Estados Unidos de América, Irán, Noruega, Nueva Zelanda, Suiza
Fludarin India
Fludarosa Argentina
Forclina Marruecos
Ludabina Chile, Colombia
Mepredin Marruecos
Naprobin India
Neoflubin Irán
Bibliografía   Inyectables   Bibliografía : Fludarabine phosphate  
Tipo Publicación
3 periódico Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81 periódico Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 periódico Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 periódico Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 periódico Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 periódico Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 periódico Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 periódico Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307 periódico Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
492 periódico Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
905 periódico Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1410 periódico Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 periódico Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
2344 Laboratorio Stabilité physico-chimique de la gamme oncologie Ebewe Pharma France après dilution.
Ebewe Pharma 2009
3306 periódico Trittler R.
New stability studies for fludarabine according to the European Pharmacopoeia 7.0
EJOP 2012 ; 6, 1: 1-2.
3595 Laboratorio Aciclovir - Summary of Product Characteristics
Hospira 2009
3604 Laboratorio Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2012
3637 Laboratorio Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics
Hameln Pharmaceuticals 2014
3644 Laboratorio Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3670 periódico Sewell G, Massimini M.
Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system.
EJOP 2014 ; 8, 3: 26-30.
3838 Laboratorio Magnesium Sulphate - Summary of Product Characteristics
Martindale Pharmaceuticals Ltd 2007
4398 periódico Smith E. K., Shergold J.A., McWhinney B.C.
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush.
J Pharm Pract and Res 2020

  Mentions Légales